Market Size of Global Saliva Collection and Diagnosis Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.10 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Saliva Collection and Diagnostics Market Analysis
The saliva collection and diagnosis market are projected to register a CAGR of 10.1% during the forecast period (2022-2027).
COVID-19 has had a significant impact on the growth of the market, owing to the rising cases of infectious diseases among people and an increased preference for non-invasive and self-saliva-based tests. The increase in the need to diagnose COVID-19 infected patients created lucrative opportunities for the saliva collection and diagnosis market. For instance, according to the World Health Organization (WHO), in January 2022, the number of new COVID-19 cases increased by 5% across the globe from January 17th to January 23rd, 2022. Additionally, initiatives taken by the market players also contributed to the growth of the market. For instance, in December 2021, Cotipharma launched a saliva-based Omicron detecting PCR test in Africa. This test is CE-marked and can detect all known variants of SARS-CoV-2, including Omicron. Thus, COVID-19 is expected to have a significant impact on the growth of the market.
Furthermore, the increasing prevalence of infectious diseases among people across the globe is assumed to be one of the major driving factors for market growth. According to the World Health Organization (WHO), in 2021, 60% of the global population suffered from infectious diseases. The report also stated that infectious diseases kill over 17 million people a year, which illustrates the global burden of infectious diseases. The rise in the number of infectious cases has led to the demand for safe and effective diagnostic tests and products. Hence, saliva collection and diagnosis play a major role as a non-invasive diagnostic method for screening patients for several diseases.
Moreover, the increase in product approvals for saliva collection and diagnostic products is a significant factor likely to augment the market's growth. For instance, in July 2021, Hologic Inc.'s HOLX optima SARS-COV-2 molecular diagnostic test received CE marking by the European Union for its use with a saliva sample.
Additionally, the initiatives taken by the public authorities are also propelling the growth of the market. For instance, in August 2022, Australia launched one of the world's first preventative DNA screening programs for cancer and heart disease risk through free DNA saliva tests. It is a nationally collaborative project, led by Australia's Monash University. Furthermore, the initiatives taken by market players to support labs in conducting scientific studies using banked saliva samples, taking advantage of a sample type that is easy to access and non-invasive, are expected to have a positive impact on the growth of the market. For instance, in September 2021, Thermo Fisher Scientific launched the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit, which is designed to safely collect saliva for research. Such initiatives also contribute to the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, the high cost of collection devices may impede the growth of the market.
